SCHEMBL16633449

SCHEMBL16633449

CCC(=O)C(c1ccc(OC(F)(F)F)cc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
PDE2A O00408 2/20 0.38
POLB P06746 1/20 0.38
HRH3 Q9Y5N1 4/20 0.37
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
EPHX1 P07099 2/20 0.37
SERPINE1 P05121 1/20 0.37
PPARD Q03181 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
EPHX2 P34913 3/20 0.36
CNR2 P34972 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16633233 0.84 EPHX1 (0.43) ALDH1A1PDE2APOLBPPARGPPARA
SCHEMBL16633394 0.83 ALDH1A1 (0.38) ALDH1A1PDE2APPARGPPARAEPHX1
SCHEMBL16633661 0.82 EPHX2 (0.40) ALDH1A1PDE2APPARGPPARAPPARD
SCHEMBL16633285 0.80 ALDH1A1 (0.36) ALDH1A1PDE2APPARGPPARAEPHX1
SCHEMBL16633980 0.79 ALDH1A1 (0.41) ALDH1A1PDE2APOLBHRH3PPARA
SCHEMBL16633268 0.79 ALDH1A1 (0.39) ALDH1A1PDE2APOLBHRH3PPARG
SCHEMBL16634078 0.78 EPHX1 (0.40) ALDH1A1PDE2APOLBEPHX1SERPINE1
SCHEMBL16563726 0.77 TRPV1 (0.40) ALDH1A1PDE2AEPHX1SERPINE1EPHX2
SCHEMBL16633204 0.77 MMP2 (0.40) ALDH1A1PDE2APOLBEPHX1SERPINE1
SCHEMBL16632995 0.76 EPHX1 (0.41) ALDH1A1PPARGPPARAEPHX1SERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A ALDH1A1 492/4885PDE2A 1/4885POLB 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.